Pfizer and Takeda, which previously backed a $15m series A, have returned to back a $76m series B round for Cortexyme.

Cytrellis has raised $28.5m from investors including pharmaceutical developer Merz as it continues clinical trials on its handheld dermatological device for aging skin.

Trust Ventures has secured $35m for its inaugural fund from investors including Koch Disruptive Technologies to invest in sectors where public policy is proving a hurdle to startups.

Quest Diagnostics returned to back a $26m funding round for Clinical Genomics, which is working on a colorectal cancer test.

The spinout has bagged support from Inserm Transfert Initiative and two Bpifrance-managed funds for its clinical-stage therapy for hepatitis B.

In 2016, Ava closed an oversubscribed $9.7m series A round backed by telecommunications company Swisscom and financial services provider Zurich Cantonal Bank.

The funding will go towards expanded research and development activities at AbSci, which has created a a synthetic biology platform.